NASDAQ: PCVX

Vaxcyte, Inc.

Healthcare | Biotechnology

No licensed closing price on file for PCVX. This page shows the company’s SEC filings and filed figures, without a price or any ratio that depends on one.

Vaxcyte, Inc. (NASDAQ: PCVX) is a biotechnology company. Figures from SEC EDGAR; updated 2026-10-20 09:47 UTC.

What Vaxcyte, Inc. does

This company is a clinical-stage vaccine developer using a cell-free protein synthesis platform called XpressCF to create vaccines against bacterial diseases. The company is developing pneumococcal conjugate vaccines (PCVs) designed to protect against a broader range of disease-causing strains than currently available vaccines. Its lead candidate, VAX-31, is a broad-spectrum vaccine in development for both adult and pediatric indications to prevent invasive pneumococcal disease and pneumonia.

Summarized from Vaxcyte, Inc.’s SEC filings · AI-generated analysis. Not investment advice. May contain errors. · Read the filing ↗

Key facts

Charts

Charts are in the appInteractive charts for PCVX are available in Oxford Ledge.
Open PCVX in Oxford Ledge →

SEC Filings

SEC EDGAR ↗

Recent Insider Activity (last 90 days)

Source: SEC EDGAR · Filed 2026-10-07

2026-10-07SVP, Finance & CAOOption exercise19,000$492.5K
2026-10-07EVP, Chief Scientific Ofc, COOOption exercise18,000$96.3K
2026-10-07SVP, Finance & CAOSale-19,000$1.65M

Top Institutional Holders (latest 13F)

Source: SEC EDGAR · As of 2026-Q2

FMR LLC20,852,907$1.21B+26.4%
Jupiter Topco LLC17,965,847$1.04BNEW
BlackRock, Inc.12,068,129$701.52M+29.6%

View QoQ ownership changes →Full institutional ownership →

Recent 8-K Events (parsed from SEC filings)All events →

Source: SEC EDGAR 8-K filings · Interpretation: Oxford Ledge parser · Confidence-filtered ≥ 0.50

2025-12-19Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →
2025-05-01Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersOlivier BrandicourtEstimatedSEC 8-K →
2022-12-12Exec ChangeDeparture of directors or certain officers; election of directors; appointment of certain officers; compensatory arrangements of certain officersEstimatedSEC 8-K →

Company news

View all →

Vaxcyte: Vaccine Titan In The Making
Seeking Alpha Feed2026-10-19
Vaxcyte: Vaccine Titan In The Making
SeekingAlpha2026-10-19
Wall Street Analysts Think Vaxcyte (PCVX) Could Surge 75.6%: Read This Before Placing a Bet
Yahoo2026-10-14POS
Cantor Fitzgerald Reiterates Overweight on Vaxcyte, Announces $120 Price Target
Benzinga2026-10-12
Vaxcyte Announces Closing of $1.15 Billion Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes, Including Full Exercise of Underwriters’ Options to Purchase Additional Shares and Convertible Senior Notes
Yahoo2026-10-09

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for PCVX and 5,000+ tickers.

Create a free account — keep PCVX

For your agent

GET /api/data?ticker=PCVX

This page as JSON via rel="alternate" · REST API docs · MCP server (60 tools) · llms.txt